The Generics Bulletin Top 50, Part Two: Mid-Table Firms Move Up And Down

As Certain Companies Ascend, Others Are Moving In The Opposite Direction

02 Aug 2023

In the second part of Generics Bulletin’s Top 50, we look at the mid-table players and how they have shifted positions this year.

Generics Bulletin Top 50 2023 — Ups and downs have been seen in the middle of our ranking • Source: Shutterstock

With two new spaces having opened up in our rundown of the top 10 generics and biosimilars companies this year – allowing Dr Reddy’s and Cipla to ascend out of the middle table covering positions 11-30 in our ranking, and into the top 10 (see sidebar) – this has left room for further firms to climb up the charts in the second part of the Generics Bulletin Top 50.

Intas – parent company of Accord – now tops the second table, providing financial details directly to Generics Bulletin. The...